Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Inclusion Criteria: * Recurrent or metastatic NPC incurable by local therapies and failed at least 2 lines of previous chemotherapy with at least 1 line including platinum based chemotherapy * Measurable disease (RECIST 1.1) * ECOG 2 or less * Life expectancy greater than 3 months * Adequate organ function * (Provided tissue for PD-L1 biomarker analysis from a core or excisional biopsy Paired biopsy of baseline tissue at first diagnosis and for recurrence if possible) - optional but encouraged Exclusion Criteria: * Suitable for local therapy * Did not have prior platinum chemotherapy * Immunodeficiency; immunosuppressive treatment * Anti-cancer monoclonal antibody treatment within 4 weeks prior to Day 1 * Other cancer treatment within 2 weeks prior to Day 1 * Other malignancies (some exceptions) * CNS metastases; carcinomatous meningitis * Active temporal lobe necrosis or on steroid treatment * Autoimmune disease * Active, non-infectious pneumonitis * Active infection requiring systemic treatment * Hepatitis